PCR Journal Club

The investigators proposed rapid atrial pacing (RAP) to further risk-stratify patients for post-TAVR PPI. Atrial pacing can be easily performed during the TAVR procedure since a temporary pacemaker (TPM) is routinely positioned in the right ventricle during valve implantation.

This retrospective study represents the first direct comparison among different transcatheter SEVs in patients characterized by small annuli undergoing TAVI.

In the absence of randomized trials to study TAVR in bicuspid arotic stenosis in low-risk patients, prospective cohort studies such as Low-Risk TAVR provide us with valuable information.

Valve-in-valve transcatheter aortic valve implantation (VIV TAVI) over the last few years has been regarded as a reasonable treatment option for patients with failed surgical bioprostheses who are at increased risk for surgical reoperation and suitable anatomical features. While VIV TAVI showed good short-term hemodynamic and...

This study reports the results of using the Left ventricular (LV) guidewire for pacing instead of introducing a temporary RV pacing wire. The safety of this approach is weighed against the potential complications of temporary pacing wires that include access and right ventricular perforation.

Concomitant coronary artery disease (CAD) is frequently found in patients with severe aortic stenosis (AS) undergoing treatment with transcatheter aortic valve implantation (TAVI).

The RECOVERY trial sought to compare long-term clinical outcomes of early surgical AVR with conservative care strategy according to the current guidelines in asymptomatic patients with very severe AS.

The GALILEO trial was a randomized, open-label, event-driven, international, multicentre trial comparing two different preventive strategies for thromboembolic complications in patients who underwent successful TAVI and had not established indication for oral anticoagulation.

This study compared the outcomes of TAVR in patients with pure Aortic Stenosis (i.e., without or trivial AR) vs. patients with MAVD (AS associated with mild to moderate or severe AR).

Although multiple studies have demonstrated an early health status benefit with TAVI vs. SAVR , this is the first randomized trial to demonstrate a persistent, albeit modest, health status advantage with TAVI at 6 and 12 months—timepoints at which patients are assumed to have recovered fully...